Tissue Repair Peptide Blend
Dragon Pharma Peptide Product
Dragon Pharma TB 500/BPC 157 is supplied as a lyophilized powder in a 2 mL vial and contains a combination of two peptides: TB 500 and BPC 157, each at a labeled strength of 5 mg. Product specifications, a batch-specific lab report, storage information, and available payment options are provided below.
Contains equal amounts (5 mg each) of TB 500 and BPC 157 per vial.
Supplied as a freeze-dried powder requiring reconstitution with bacteriostatic water before use.
Packaged in a standard 2 mL peptide vial with a rubber stopper and aluminum seal.
A published lab report from April 2024 provides measured results for the identified batch.
| Product name | TB 500 5 mg/BPC 157 5 mg |
|---|---|
| Active substances | TB 500 (5 mg), BPC 157 (5 mg) |
| Total labeled strength | 10 mg/vial |
| Container | 2 mL vial |
| Total labeled content | 10 mg per vial |
| Product form | Lyophilized powder |
| Manufacturer | Dragon Pharma |
The latest published report for batch #BTHD24, dated April 26, 2024, measured 5.43 mg of TB 500 and 4.95 mg of BPC 157 against the stated 5 mg labeled strength for each peptide.
Open the Lab Reports tab to view the full report and check the batch number associated with the test.
Other peptide options from the same product line include TB 500 5 mg and BPC 157 5 mg as individual peptides, and Glow 60 mg, which combines TB-500 with BPC-157 and GHK-CU. These products differ in their peptide composition and research applications.
Published Test Result
A published lab report for Dragon Pharma TB 500/BPC 157 is provided below with the test date, measured results and reported batch number. Each result can be compared directly with the product's labeled strength of 5 mg per peptide.
Science & Research
TB 500 and BPC 157 are synthetic peptides that have each been investigated in preclinical research for their potential roles in tissue repair and related cellular processes. This section provides a brief overview of what is known about these peptides from research literature.
TB 500 is a synthetic peptide that corresponds to a fragment of the naturally occurring protein thymosin beta-4. Research has investigated its potential role in cell migration, tissue repair, and cytoskeletal regulation.
BPC 157 is a synthetic peptide derived from a gastric juice protein. Preclinical research has investigated its potential effects on tissue repair, angiogenesis, and the protection of various tissues. Its mechanism of action is not fully characterized.
Combining TB 500 and BPC 157 is a research approach that uses two distinct peptides with potential roles in tissue repair. The combined effects and potential interactions of these peptides have not been fully characterized in research.
This product is supplied as a lyophilized powder and must be reconstituted with bacteriostatic water or sterile water for injection before use. The addition of water converts the freeze-dried powder into a solution suitable for research applications.
The reconstituted peptide solution should be stored as recommended on the product label. Peptide solutions are typically refrigerated and used within a specified timeframe after reconstitution to maintain integrity.
Peer-reviewed research on TB 500 (thymosin beta-4) and BPC 157 is available through the National Institutes of Health and other scientific databases. The following links provide general information on these peptides and their mechanisms of action.
Important Health Information
Peptide research compounds such as those in this blend have limited clinical safety data. The information below is derived from published preclinical research and general knowledge of peptide biology and does not constitute medical advice.
TB 500 and BPC 157 have not been extensively studied in humans. The available safety information comes primarily from preclinical research.
The potential interactions and combined effects of TB 500 and BPC 157 have not been characterized in research. The significance of combining them is not fully understood.
Subcutaneous injection carries risks including injection-site reactions, infection and improper technique. Sterile handling and correct reconstitution procedures are essential.
The potential systemic effects of these peptides and their interactions with other physiological systems are not fully understood.
This peptide research compound should not be used by individuals with known allergies or sensitivities to peptide compounds, or by those who are pregnant, nursing or have active malignancies.
The long-term effects and safety profile of this peptide blend have not been established in any population. Research on these peptides is still in the early stages.
Medical advice is particularly important for individuals with autoimmune conditions, cancer or a history of cancer, cardiovascular disease, or those taking medications that affect immune function or angiogenesis. This peptide blend should not be used during pregnancy or breastfeeding.
The product should also be stored securely to prevent accidental access or use by children or other household members, particularly after reconstitution when it contains a liquid solution.
TB 500 (thymosin beta-4) and BPC 157 are not specifically listed on the World Anti-Doping Agency Prohibited List at the time of writing. Athletes should check the current list before competition, as prohibited substances are subject to change. Some peptide compounds may fall under general prohibitions on substances with similar biological effects.
The current status and applicable rules can be checked through the World Anti-Doping Agency Prohibited List.
Common Product Questions
Quick answers about TB 500/BPC 157 specifications, the published lab report, storage, shipping, Bitcoin payment and general product information.
Dragon Pharma TB 500/BPC 157 is a lyophilized peptide product containing 5 mg of TB 500 and 5 mg of BPC 157 per vial. It is supplied in a 2 mL vial for research purposes.
TB 500 is a synthetic peptide corresponding to a fragment of thymosin beta-4, while BPC 157 is a synthetic peptide derived from a gastric juice protein. Both have been investigated in preclinical research for their potential roles in tissue repair.
Each vial contains a labeled strength of 5 mg of TB 500 and 5 mg of BPC 157, for a total of 10 mg of peptide content per vial.
The product is supplied as a lyophilized powder in a 2 mL vial. It requires reconstitution with bacteriostatic water or sterile water for injection before use.
The published lab report dated April 26, 2024 for batch #BTHD24 measured 5.43 mg of TB 500 and 4.95 mg of BPC 157 against the stated 5 mg labeled strength for each peptide.
No. Each report applies to the sample submitted for that specific test and the batch identified in the report. It does not independently verify the content or condition of every individual vial.
Store the lyophilized powder in its original packaging at room temperature or refrigerated, protected from excessive heat, moisture and direct light. Once reconstituted, peptide solutions typically require refrigeration and should be used within a limited timeframe. Always follow the specific storage directions printed on the product label.
Lyophilized peptide powders are generally stable at room temperature but should be protected from heat. After reconstitution, peptide solutions typically require refrigeration. Check the product label for specific storage instructions.
Delivery depends on the warehouse selected for the order. Shipments from the USA Warehouse typically take 4–5 business days after dispatch, while shipments from the International Warehouse typically take 15–20 business days after dispatch. Full delivery and reship information is available on the Shipping Information page.
Yes. Bitcoin and other supported cryptocurrencies are available at checkout for all orders. To buy TB 500/BPC 157 with Bitcoin, select Bitcoin as the payment method during checkout and follow the payment instructions provided with the order.
Bitcoin transactions are recorded on a public blockchain and should not be considered automatically anonymous. Accurate order and delivery information is still required for order processing and shipping.
TB 500 and BPC 157 are not specifically listed on the World Anti-Doping Agency Prohibited List at the time of writing. Athletes should check the current list before competition, as prohibited substances are subject to change.
Additional research on TB 500 (thymosin beta-4) and BPC 157 is available through the National Institutes of Health and other scientific databases. Direct links to PubMed references are provided in the Science & Research section above.
Please log in to write TB 500 5 mg/BPC 157 5 mg review.